Boundless Bio Inc./$BOLD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
- Ticker
- $BOLD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 28
- Headquarters
- San Diego, United States
- Website
- boundlessbio.com
BOLD Metrics
BasicAdvanced
$56M
-
-$2.86
0.47
-
Price and volume
Market cap
$56M
Beta
0.47
52-week high
$3.16
52-week low
$0.96
Average daily volume
148K
Financial strength
Current ratio
9.481
Quick ratio
9.349
Profitability
EBITDA (TTM)
-64.226
Management effectiveness
Return on assets (TTM)
-32.77%
Return on equity (TTM)
-67.86%
Valuation
Price to book
0.83
Price to tangible book (TTM)
0.83
Price to free cash flow (TTM)
-0.968
Free cash flow yield (TTM)
-103.33%
Free cash flow per share (TTM)
-2.531
Growth
Earnings per share change (TTM)
-0.96%
3-year earnings per share growth (CAGR)
-59.20%
What the Analysts think about BOLD
Analyst ratings (Buy, Hold, Sell) for Boundless Bio Inc. stock.
Analyst projections of the future price of Boundless Bio Inc. stock.
BOLD Financial Performance
Revenues and expenses
BOLD Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.